Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1998 2
1999 9
2000 6
2001 11
2002 11
2003 19
2004 16
2005 23
2006 13
2007 16
2008 15
2009 6
2010 5
2011 9
2012 10
2013 10
2014 5
2015 7
2016 9
2017 10
2018 13
2019 20
2020 14
2021 27
2022 36
2023 34
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Results by year

Filters applied: . Clear all
Page 1
Lonafarnib: First Approval.
Dhillon S. Dhillon S. Drugs. 2021 Feb;81(2):283-289. doi: 10.1007/s40265-020-01464-z. Drugs. 2021. PMID: 33590450 Free PMC article. Review.
Lonafarnib is under regulatory review in the European Union. Clinical development for the treatment of HDV infections is underway in multiple countries. This article summarizes the milestones in the development of lonafarnib leading to this first approval....
Lonafarnib is under regulatory review in the European Union. Clinical development for the treatment of HDV infections is underway in …
Lonafarnib.
[No authors listed] [No authors listed] 2021 Jan 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Jan 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 33560735 Free Books & Documents. Review.
Lonafarnib is an oral, small molecule inhibitor of farnesyltransferase that is used to treat Hutchison-Gilford progeria syndrome and is under investigation as therapy of chronic hepatitis D. Lonafarnib is associated with transient and usually mild elevations in seru …
Lonafarnib is an oral, small molecule inhibitor of farnesyltransferase that is used to treat Hutchison-Gilford progeria syndrome and …
Lonafarnib.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Apr 22;78(9):755-757. doi: 10.1093/ajhp/zxab034. Am J Health Syst Pharm. 2021. PMID: 33684937 No abstract available.
Lonafarnib-A new member of the Delta Force?
Dietz CA, Cornberg M. Dietz CA, et al. Hepatology. 2022 Jun;75(6):1370-1372. doi: 10.1002/hep.32435. Epub 2022 Mar 13. Hepatology. 2022. PMID: 35229339 No abstract available.
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee AK, Johnson K, Morwood K, Rox K, Elgaher WAM, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët JF, Rameix-Welti MA, Hirsch AKH, Herold E, Empting M, Lauber C, Schulz TF, Krey T, Haid S, Pietschmann T. Sake SM, et al. Nat Commun. 2024 Feb 8;15(1):1173. doi: 10.1038/s41467-024-45241-y. Nat Commun. 2024. PMID: 38332002 Free PMC article. Review.
Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystal …
Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mut …
Lonafarnib for cancer and progeria.
Wong NS, Morse MA. Wong NS, et al. Expert Opin Investig Drugs. 2012 Jul;21(7):1043-55. doi: 10.1517/13543784.2012.688950. Epub 2012 May 24. Expert Opin Investig Drugs. 2012. PMID: 22620979 Review.
Although extensive clinical research indicates limited activity of lonafarnib in solid tumors, there is recent interest in combinations of farnesyl transferase inhibitors with imatinib or bortezomib in hematological malignancies and to investigate the role of lonafarnib …
Although extensive clinical research indicates limited activity of lonafarnib in solid tumors, there is recent interest in combinatio …
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
Murtada SI, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra AB, Li DS, Braddock DT, Tellides G, Gordon LB, Humphrey JD. Murtada SI, et al. Elife. 2023 Mar 17;12:e82728. doi: 10.7554/eLife.82728. Elife. 2023. PMID: 36930696 Free PMC article.
The US Food and Drug Administration approved Zokinvy (lonafarnib) in November 2020 for treating these patients, yet a detailed examination of drug-associated effects on cardiovascular structure, properties, and function has remained wanting. ...By contrast, neither treatme …
The US Food and Drug Administration approved Zokinvy (lonafarnib) in November 2020 for treating these patients, yet a detailed examin …
Lonafarnib in cancer therapy.
Morgillo F, Lee HY. Morgillo F, et al. Expert Opin Investig Drugs. 2006 Jun;15(6):709-19. doi: 10.1517/13543784.15.6.709. Expert Opin Investig Drugs. 2006. PMID: 16732721 Review.
This review describes the pharmacological and clinical data as well as mechanisms of action of FTIs, especially lonafarnib (SCH-66336), a non-peptidomimetic inhibitor that has shown anticancer activity....
This review describes the pharmacological and clinical data as well as mechanisms of action of FTIs, especially lonafarnib (SCH-66336 …
Hutchinson-Gilford Progeria Syndrome: A Literature Review.
Lamis A, Siddiqui SW, Ashok T, Patni N, Fatima M, Aneef AN. Lamis A, et al. Cureus. 2022 Aug 31;14(8):e28629. doi: 10.7759/cureus.28629. eCollection 2022 Aug. Cureus. 2022. PMID: 36196312 Free PMC article. Review.
Correction to: Lonafarnib: First Approval.
Dhillon S. Dhillon S. Drugs. 2021 Apr;81(5):619. doi: 10.1007/s40265-021-01500-6. Drugs. 2021. PMID: 33755935 Free PMC article. No abstract available.
333 results